Variant · Snv
FLT3 N676K
CI-VAR-00002927Explore in graph →CIViC 3053
Curated evidence
Evidence by cancer (3 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23878140
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Core Binding Factor Acute Myeloid Leukemia1 | ||||||||
| FLT3 N676K | Midostaurin + QuizartinibSequential | Predictive | B | Supports N/A | 3 | submitted | EID8263In a cohort of 84 de novo AML patients with a CBFB/MYH11 rearrangement and in 36 patients with a RUNX1/RUNX1T1 rearrangement, the FLT3 N676K mutation was identified in 5 and 1 patients, respectively (… (full text at CIViC) PMID 23878140 · Opatz et al., 2013 · Open in CIViC | civic |
| Leukemia1 | ||||||||
| FLT3 N676K | (oncogenic) | Oncogenic | D | Supports Oncogenicity | 3 | submitted | EID9530The ability of FLT3-N676K mutation to induce leukemia by itself in mouse models is explored in this study. Furthermore, the leukemogenic potential of FLT3-N676K is compared to two well established, ca… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available